Download PDF
Semin Thromb Hemost 2013; 39(07): 740-751
DOI: 10.1055/s-0033-1354417
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Identifying Nongenetic Risk Factors for Inhibitor Development in Severe Hemophilia A

Samantha C. Gouw
1   Department of Pediatric Haematology, Emma Children's Hospital, Academic Medical Centre Amsterdam, Amsterdam, The Netherlands
,
Karin Fijnvandraat
1   Department of Pediatric Haematology, Emma Children's Hospital, Academic Medical Centre Amsterdam, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
08 September 2013 (online)

    Permissions and Reprints

Abstract

The development of inhibitory antibodies against infused factor VIII (FVIII) is a major challenge in hemophilia treatment. As the antibodies swiftly inactivate administered therapeutic FVIII concentrates, FVIII is no longer effective in controlling bleeding. To achieve adequate hemostasis, bypassing therapies are required, with accompanying clinical challenges and financial expense. Extensive research has aimed to elucidate the multifactorial etiology of inhibitor development. Both genetic and nongenetic causes have been identified. Identification of treatment-related risk factors would offer the possibility to modify treatment strategies in high-risk patients, thereby reducing the risk of inhibitor development. Have we presently gained sufficient knowledge to make a prediction of the inhibitor risk possible and justify changes in treatment regimens for specific patient groups? This review summarizes and evaluates the research findings on nongenetic risk factors of inhibitor development, with special focus on treatment-related factors.

Keywords

FVIII - etiology - treatment - antibody - tolerance - prophylaxis
 

  • References

  • 1 Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39 (11-12) 1160-1168
    CrossrefPubMedGoogle Scholar
  • 2 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9 (4) 418-435
    CrossrefPubMedGoogle Scholar
  • 3 Gringeri A, Mantovani LG, Scalone L, Mannucci PM ; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (7) 2358-2363
    CrossrefPubMedGoogle Scholar
  • 4 Leissinger C, Cooper DL, Solem CT ; HTRS Investigators. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A. Haemophilia 2011; 17 (6) 884-889
    CrossrefPubMedGoogle Scholar
  • 5 Morfini M, Haya S, Tagariello G , et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13 (5) 606-612
    CrossrefPubMedGoogle Scholar
  • 6 Hay CR, DiMichele DM ; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119 (6) 1335-1344
    CrossrefPubMedGoogle Scholar
  • 7 Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9 (4) 436-463
    CrossrefPubMedGoogle Scholar
  • 8 Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK ; MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107 (8) 3167-3172
    CrossrefPubMedGoogle Scholar
  • 9 Astermark J, Oldenburg J, Carlson J , et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108 (12) 3739-3745
    CrossrefPubMedGoogle Scholar
  • 10 Astermark J, Donfield SM, Gomperts ED , et al; Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood 2013; 121 (8) 1446-1454
    CrossrefPubMedGoogle Scholar
  • 11 Gouw SC, van den Berg HM, Oldenburg J , et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119 (12) 2922-2934
    CrossrefPubMedGoogle Scholar
  • 12 Hay CR, Ollier W, Pepper L , et al; UKHCDO Inhibitor Working Party. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost 1997; 77 (2) 234-237
    PubMedGoogle Scholar
  • 13 Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77 (2) 238-242
    PubMedGoogle Scholar
  • 14 Schwaab R, Brackmann HH, Meyer C , et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74 (6) 1402-1406
    PubMedGoogle Scholar
  • 15 Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045
    CrossrefPubMedGoogle Scholar
  • 16 Reipert BM, van Helden PM, Schwarz HP, Hausl C. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haematol 2007; 136 (1) 12-25
    CrossrefPubMedGoogle Scholar
  • 17 Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109 (11) 4648-4654
    CrossrefPubMedGoogle Scholar
  • 18 Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5 (7) 1383-1390
    CrossrefPubMedGoogle Scholar
  • 19 Maclean PS, Richards M, Williams M , et al; Paediatric Working Party of UKHCDO. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia 2011; 17 (2) 282-287
    CrossrefPubMedGoogle Scholar
  • 20 Gouw SC, van den Berg HM, Fischer K , et al; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121 (20) 4046-4055
    CrossrefPubMedGoogle Scholar
  • 21 Eckhardt CL, van der Bom JG, van der Naald M, Peters M, Kamphuisen PW, Fijnvandraat K. Surgery and inhibitor development in hemophilia A: a systematic review. J Thromb Haemost 2011; 9 (10) 1948-1958
    CrossrefPubMedGoogle Scholar
  • 22 Rivard GE, Lillicrap D, Poon MC , et al. Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?. Haemophilia 2005; 11 (4) 335-339
    CrossrefPubMedGoogle Scholar
  • 23 Santagostino E, Mancuso ME, Rocino A , et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130 (3) 422-427
    CrossrefPubMedGoogle Scholar
  • 24 Kenet G, Lubetsky A, Luboshitz J , et al. Early single exposure to factor concentrates does not increase the risk for inhibitor development. Haemophilia 2006; 12 (Suppl. 02) 63 (abstract 14 PO 395)
    PubMedGoogle Scholar
  • 25 Elalfy MS, Elbarbary NS, Eldebeiky MS, El Danasoury AS. Risk of bleeding and inhibitor development after circumcision of previously untreated or minimally treated severe hemophilia A children. Pediatr Hematol Oncol 2012; 29 (5) 485-493
    CrossrefPubMedGoogle Scholar
  • 26 Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010; 16 (2) 256-262
    CrossrefPubMedGoogle Scholar
  • 27 Auerswald G, Bidlingmaier C, Kurnik K. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients—long-term follow-up and continuing experience. Haemophilia 2012; 18 (1) e18-e20
    CrossrefPubMedGoogle Scholar
  • 28 Morado M, Villar A, Jiménez Yuste V, Quintana M, Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 2005; 11 (2) 79-83
    CrossrefPubMedGoogle Scholar
  • 29 Shirahata A, Fukutake K, Higasa S , et al; STUDY GROUP ON FACTORS INVOLVED IN FORMATION OF INHIBITORS TO FACTOR VIII AND IX PREPARATIONS. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan. Haemophilia 2011; 17 (5) 771-776
    PubMedGoogle Scholar
  • 30 Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76 (5) 749-754
    PubMedGoogle Scholar
  • 31 Wadhwa M, Dilger P, Tubbs J, Mire-Sluis A, Barrowcliffe T, Thorpe R. Identification of transforming growth factor-beta as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs. Blood 1994; 84 (6) 2021-2030
    PubMedGoogle Scholar
  • 32 Raut S, Weller L, Barrowcliffe TW. Phospholipid binding of factor VIII in different therapeutic concentrates. Br J Haematol 1999; 107 (2) 323-329
    CrossrefPubMedGoogle Scholar
  • 33 Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol 2012; 81 (1) 82-93
    CrossrefPubMedGoogle Scholar
  • 34 Iorio A, Halimeh S, Holzhauer S , et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8 (6) 1256-1265
    CrossrefPubMedGoogle Scholar
  • 35 Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13 (Suppl. 05) 65-68
    CrossrefPubMedGoogle Scholar
  • 36 Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69 (2) 115-118
    PubMedGoogle Scholar
  • 37 Rosendaal FR, Nieuwenhuis HK, van den Berg HM , et al; Dutch Hemophilia Study Group. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood 1993; 81 (8) 2180-2186
    PubMedGoogle Scholar
  • 38 Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109 (11) 4693-4697
    CrossrefPubMedGoogle Scholar
  • 39 Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost 2011; 9 (11) 2180-2192
    CrossrefPubMedGoogle Scholar
  • 40 Iorio A, Marcucci M, Makris M. Concentrate-related inhibitor risk: is a difference always real?. J Thromb Haemost 2011; 9 (11) 2176-2179
    CrossrefPubMedGoogle Scholar
  • 41 Gouw SC, van der Bom JG, Ljung R , et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368 (3) 231-239
    CrossrefPubMedGoogle Scholar
  • 42 Giangrande PL ; KOGENATE Bayer Study Group. Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia 2002; 8 (Suppl. 02) 19-22
    CrossrefPubMedGoogle Scholar
  • 43 Kreuz W, Gill JC, Rothschild C , et al; International Kogenate-FS Study Group. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005; 93 (3) 457-467
    PubMedGoogle Scholar
  • 44 Pahl S, Pavlova A, Driesen J, Müller J, Pötzsch B, Oldenburg J. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile. Haemophilia 2013; 19 (3) 392-398
    CrossrefPubMedGoogle Scholar
  • 45 Baglin T, Beacham E. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?. Thromb Haemost 1998; 80 (6) 1036-1037
    PubMedGoogle Scholar
  • 46 Bacon CL, Singleton E, Brady B , et al. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®). Haemophilia 2011; 17 (3) 407-411
    CrossrefPubMedGoogle Scholar
  • 47 Kocher S, Asmelash G, Makki V , et al. [Inhibitor development after changing FVIII/IX products in patients with haemophilia]. Hamostaseologie 2012; 32 (Suppl. 01) S39-S42
    PubMedGoogle Scholar
  • 48 Janeway Jr ChA, Travers P, Walport M. Principles of innate and adaptive immunity. In: Immunobiology: The Immune System in Health and Disease. 5th ed. New York: Garland Science; 1997. 1. :1–1:30
    Google Scholar
  • 49 Peng A, Gaitonde P, Kosloski MP, Miclea RD, Varma P, Balu-Iyer SV. Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice. J Pharm Sci 2009; 98 (12) 4480-4484
    CrossrefPubMedGoogle Scholar
  • 50 Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang 1999; 77 (Suppl. 01) 49-54
    CrossrefPubMedGoogle Scholar
  • 51 Strauss T, Lubetsky A, Ravid B , et al. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study. Haemophilia 2011; 17 (4) 625-629
    CrossrefPubMedGoogle Scholar
  • 52 Yee TT, Lee CA. Oral immune tolerance induction to factor VIII via breast milk, a possibility?. Haemophilia 2000; 6 (5) 591
    CrossrefPubMedGoogle Scholar
  • 53 Jansen IM, Fischer K, Van Der Bom JG, Van Den Berg HM. No protective effect of breastfeeding on inhibitor formation in severe hemophilia. Pediatr Hematol Oncol 2005; 22 (7) 575-580
    CrossrefPubMedGoogle Scholar
  • 54 Knobe KE, Tengborn LI, Petrini P, Ljung RC. Breastfeeding does not influence the development of inhibitors in haemophilia. Haemophilia 2002; 8 (5) 657-659
    CrossrefPubMedGoogle Scholar
  • 55 von Auer Ch, Oldenburg J, von Depka M , et al. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci 2005; 1051: 498-505
    CrossrefPubMedGoogle Scholar
  • 56 Auerswald G, Bade A, Haubold K, Overberg D, Masurat S, Moorthi C. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study. Haemophilia 2013; 19 (3) 438-444
    CrossrefPubMedGoogle Scholar
  • 57 Batorova A, Holme P, Gringeri A , et al; European Haemophilia Treatment Standardisation Board. Continuous infusion in haemophilia: current practice in Europe. Haemophilia 2012; 18 (5) 753-759
    Google Scholar
  • 58 Batorova A, Martinowitz U. Continuous infusion of coagulation factors: current opinion. Curr Opin Hematol 2006; 13 (5) 308-315
    CrossrefPubMedGoogle Scholar
  • 59 Dhadwar SS, Kiernan J, Wen J, Hortelano G. Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice. J Thromb Haemost 2010; 8 (12) 2743-2750
    CrossrefPubMedGoogle Scholar
  • 60 Kitazawa T, Igawa T, Sampei Z , et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18 (10) 1570-1574
    CrossrefPubMedGoogle Scholar
  • 61 Welch EM, Barton ER, Zhuo J , et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447 (7140) 87-91
    CrossrefPubMedGoogle Scholar
  • 62 Nathwani AC, Tuddenham EG, Rangarajan S , et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365 (25) 2357-2365
    CrossrefPubMedGoogle Scholar
  • 63 High KA. The gene therapy journey for hemophilia: are we there yet?. Blood 2012; 120 (23) 4482-4487
    CrossrefPubMedGoogle Scholar
  • 64 Wang J, Lozier J, Johnson G , et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol 2008; 26 (8) 901-908
    CrossrefPubMedGoogle Scholar
  • 65 Barbosa MD, Celis E. Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses. Drug Discov Today 2007; 12 (15-16) 674-681
    CrossrefPubMedGoogle Scholar